Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic.

ABSTRACT:

Objective

In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19) that resulted in a global pandemic with substantial morbidity and mortality. Currently, there is no specific treatment or approved vaccine against COVID-19. The underlying associated comorbidity and diminished immune function of some pituitary patients (whether caused by the disease and its sequelae or treatment with excess glucocorticoids) increases their risk of contracting and developing complications from COVID-19 infection.

Methods

A review of studies in PubMed and Google Scholar published between January 2020 to the time of writing (May 1, 2020) was conducted using the search terms 'pituitary,' 'co

SUBMITTER: Yuen KCJ 

PROVIDER: S-EPMC7833469 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature